Scientific Chair:
Nathalie Albert, Munich

Scientific Co-Chair:
Matthias Preusser, Vienna



DIAGNOSTIC AND THERAPEUTIC INNOVATIONS IN THE ERA OF PRECISION MEDICINE – NUCLEAR MEDICINE MEETS NEURO-ONCOLOGY

POCKET PROGRAM

NMN Symposium: Precision Medicine

07.-08. May 2026 / Vienna, Austria
Apothekertrakt Schönbrunn

www.nmn-society.org

Nuclear Medicine and Neurooncology (NMN)

Über 30 JAHRE

Forschung, Verantwortung und medizinischer Fortschritt

Aranesp® (Darbepoetin alfa)

BLINCYTO® (blinatumomab) infusion

IMLYGIC® (talimogene laherparepvec) INTRALESIONAL INJECTION

Kyprolis® (carfilzomib) Powder for solution for infusion

LUMYKRAS® (sotorasib)

MVASI® (Bevacizumab)

Neulasta® (Pegfilgrastim)

Nplate® romiplostim

Von Anfang an – 100% human Vectibix® Panitumumab

XGEVA® (denosumab)

Amgen GmbH, Franz-Josefs-Kai 47, 1010 Wien

AUT-291-0326-80009

AMGEN

TABLE OF CONTENT

Dear colleagues,

We are delighted to welcome you in Vienna for the third **"Diagnostic and Therapeutic Innovations in the Era of Precision Medicine – Nuclear Medicine Meets Neuro-Oncology (NMN)" Symposium** taking place from **May 07th - 08th, 2026!**

With the NMN Symposium we aim to provide a prime platform for networking and discussion of the most novel data the field of molecular imaging and theranostics in Neuro- Oncology. The program of the symposium will highlight the most recent findings in basic, translational, and clinical science in this exciting and evolving field of research. We are very proud and grateful for the outstanding speaker panel and faculty with top speakers from all over the world and from different specialties! Furthermore, we are very happy to have received 55 high quality submissions of original contributions that will be shared in oral and poster presentations and will surely lead to lively exchange and generate new cooperations and research ideas.

We thank the NMN Meeting Office, the Scientific Committee, and all supporters for the hard work and fantastic collaboration in organizing the symposium! Let's enjoy together the exciting scientific exchange during the main symposium program, as well as the strengthening of collaborations and friendships during our networking activities!

Welcome to Vienna - we are very excited about so many bright brains coming together for the NMN Symposium 2026!

Nathalie L. Albert
Scientific Chair

Matthias Preusser
Scientific Co-Chair

NMN Board

Matthias Preusser, Vienna, Chairperson
Nathalie L. Albert, Munich, Secretary

NMN Scientific Committee

Nathalie L. Albert, Munich, Scientific Chair
Matthias Preusser, Vienna, Scientific Co-Chair
Martin van den Bent, Rotterdam
Michael Weller, Zurich
Jolanta Kunikowska, Warsaw
Emilie Le Rhun, Zurich
Norbert Galldiks, Cologne
Marcus Hacker, Vienna
Giuseppe Minniti, Rome
Roberta Rudà, Turin
Karl Rössler, Vienna
Patrick Wen, Boston
Eng-Siew Koh, Sydney
Erik Sulman, New York
Jörg-Christian Tonn, Munich
Wim Oyen, Milan/Arnhem
Andrew Scott, Melbourne
Anna Berghoff, Vienna
Nelleke Tolboom, Utrecht
Francesco Cicone, Catanzaro
Evanthia Galanis, Rochester
Antoine Verger, Nancy
Tao Hua, Shanghai

NMN Symposium Organizer

Nuclear Medicine and Neurooncology c/o WMA GmbH
Alser Strasse 4
1090 Vienna, Austria

Scientific Management, Exhibition, Sponsorship, General Organization and Logistics

WMA GmbH
Juliana Tusa
T: +43 1 405 13 83 – 19
E: nmn@wma.co.at
W: www.nmn-society.org

WMA GmbH
WIENER MEDIZINISCHE AKADEMIE
VIENNA MEDICAL ACADEMY

Thursday, 07. May 2026

All times refer to Central European Summer Time (CEST).

09:45 – 10:00 Welcome and Introduction

- **Nuclear Medicine meets Neuro-Oncology**
  Nathalie L. Albert (Munich), Matthias Preusser (Vienna)

10:00 – 11:00 Opening Keynote Lecture

Chairs: Michael Weller (Zurich), Timothy Cloughesy (Los Angeles)

- **Designing definitive clinical trials for novel therapies in brain tumors.**
  Elizabeth Eisenhauer (Kingston) – *30+15'*

11:00 – 12:00 Understanding PET RANO criteria

- **PET RANO in clinical trials: from conception to endpoint.**
  Matthias Preusser (Vienna) – *15+5'"*
- **PET RANO in action: from guidelines to clinical cases.**
  Nathalie Albert (Munich) – *15+5'*
- **PET RANO response as primary endpoint?**
  Panel discussion: Elizabeth Eisenhauer (Kingston), Andrew Scott (Melbourne), Matthias Preusser (Vienna), Nathalie Albert (Munich) – *20'*

12:00 – 13:00 NMN Lunch

13:00 – 14:30 Clinical trials in the (hot)spotlight

Chairs: Roberta Ruda (Turin), Giuseppe Lombardi (Padua)

- **Theranostics in neuro-oncology: current clinical trial landscape.**
  Erik Sulman (Durham) – *15+15'*
- **The heat is on: clinical trials in focus.**
- **The IPAX trial series.**
  Nelleke Tolboom (Utrecht) – *15+15'*
- **LUMEN-1 and MOMENTUM-1.**
  Eng-Siew Koh (Sydney) – *15+15'*

14:30 – 15:30 Proffered papers I: Hot data and burning questions

Chairs: Emilie Le Rhun (Zurich), Marcus Hacker (Vienna)

◊ **Radionuclide Therapy with [^{177}Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort** –
Antoine Verger (Nancy), Abstract No. 6 – *5+3'*

◊ **ReSPECT-LM: Pharmacokinetic and Pharmacodynamic assessment of Reyobiq in Leptomeningeal Metastases** –
Andrew Brenner (San Antonio), Abstract No. 47 – *5+3'*

◊ **PET-Based Dosimetry of Intra-Arterial Y-90 Neurovascular Radiotherapy in Recurrent Glioblastoma: First-in-Human Feasibility** –
Kazim Narsinh (San Francisco), Abstract No. 48 – *5+3'*

◊ **Evaluation of glioblastoma-brain assembloids as an advanced in vitro model for preclinical targeted radionuclide testing** –
Sarah Waelkens (Mol), Abstract No. 37 – *5+3'*

Thursday, 07. May 2026

- ◊ **Validation of PET RANO 1.0 criteria in a retrospective, single-center cohort of patients with IDH-mutant glioma –**
  Maximilian Mair (Vienna), Abstract No. 34 – *5+3'*
- ◊ **Comparative response assessment using PET-RANO 1.0 and RANO 2.0 in vorasidenib-treated IDH-mutant gliomas: the VORAFET study –**
  Diego Cecchin (Padova), Abstract No. 8 – *5+3'*
- ◊ **Interim FDG-PET in primary central nervous system lymphoma –**
  Laura Rozenblum (Paris), Abstract No. 15 – *5+3'*

15:30 – 16:30 NMN Poster viewing with Coffee and Dessert

16:30 – 17:30 Proffered papers II: Hot data and burning questions

Chairs: Norbert Galldiks (Cologne), Antoine Verger (Nancy)

- ◊ **[18F]FET PET enables histopathology-validated detection of non-contrast-enhancing glioblastoma –**
  Roman Stürzl (Munich), Abstract No. 4 – *5+3'*
- ◊ **FET PET reveals considerable volumetric and spatial differences in tumor burden compared to conventional MRI in recurrent glioblastoma –**
  Norbert Galldiks (Cologne), Abstract No. 13 – *5+3'*
- ◊ **Prognostic relevance of FET PET in patients with newly diagnosed glioblastoma –**
  Jan-Michael Werner (Cologne), Abstract No. 42 – *5+3'*
- ◊ **Virtual postoperative 18F-FET-PET imaging as a surrogate imaging modality in recurrent glioblastoma assessment –**
  Jocelyn Castille (Brussels), Abstract No. 44 – *5+3'*
- ◊ **Identification of prognostically relevant residual tumor burden in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET –**
  Jens Blobner (Munich), Abstract No. 16 – *5+3'*
- ◊ **FET-PET in Glioblastoma (FIG) Study (TROG 18.06): Towards FET-PET-Guided Radiotherapy Target Volume Delineation in Glioblastoma –**
  Eng-Siew Koh (Sydney), Abstract No. 38 – *5+3'*
- ◊ **Mapping of Myeloid Cells in the Tumor Microenvironment of Glioblastoma using Transport Vehicle Mediated TREM2 PET Imaging –**
  Laura Bartos (Munich), Abstract No. 53 – *5+3'*

From 19:00 Networking Event

For further information see page 18

Friday, 08. May 2026

09:00 – 10:00 NMN Networking Coffee

Meet and greet:
David Collingridge (Lancet Oncology)
Ali Landmann (Lancet Medical Imaging and Theranostics)
Gelareh Zadeh (Neuro-Oncology Advances)
Matthias Preusser (Neuro-Oncology)
Maximilian Mair (EANO youngsters)

10:00 – 12:00 Innovations and controversies in theranostics

Chairs: Wim Oyen (Milan / Arnhem)

- **#increasingthepower – the rise of alpha emitters.**
  Wolfgang Wadsak (Vienna) – *15+15'*
- **#theradosetics – the concept of precision dosing in theranostics.**
  Christophe Deroose (Leuven) – *15+15'*
- **#crossingthebarrier – the role of focused ultrasound and BBB transport.**
  Roger Stupp (Chicago) – *15+15'*
- **#trialsinprogress – the future of NMN theranostics**
  - ◊ **Targeting SSTR2 With [^{212}Pb]VMT-α-NET in meningioma patients: Design of the First in Human Phase I/IIa LEMONαDE Trial** –
    Nathalie Albert (Munich), Abstract No. 55 – *3+2'*
  - ◊ **Study protocol for PRECISE, a pilot clinical trial of transarterial radioembolisation in patients with recurrent glioblastoma** –
    Gaia Ninatti (Melbourne), Abstract No. 26 – *3+2'*
  - ◊ **Intra-arterial 4- [211At]astato-L-phenylalanine ([211At]APA) in [18F]fluoroethyl-L-tyrosine ([18F]FET) positive recurrent glioblastoma: study protocol for a phase 1 dose-escalation study (I-APACHE)** –
    Anass El Ghalbouni (Utrecht), Abstract No. 5 – *3+2'*

12:00 – 13:00 NMN Lunch

13:00 – 14:30 NMN casting: theranostic targets for brain tumors – top or flop?

Chairs: Matthias Preusser (Vienna), Nathalie Albert (Munich)
Jury: Nelleke Tolboom (Netherlands), Felix Sahm (Heidelberg), Francesco Cicone (Catanzaro)

- **EGFR:** Andrew Scott (Melbourne) – *5+5'*
- **PSMA:** Sophie Veldhuijzen van Zanten (Rotterdam) – *5+5'*
- **SSTR:** Christophe Deroose (Leuven) – *5+5'*
- **FAP:** Jolanta Kunikowska (Warsaw) – *5+5'*
- **LAT1:** Jan Werner (Cologne) – *5+5'*
- **CA IX / XII:** Maximilian Mair (Vienna) – *5+5'*
- **Discussion:** all

14:30 – 15:15 NMN Coffee

Friday, 08. May 2026

15:15 – 16:45 Amino acid PET for glioma imaging – toy or tool in clinical practice?

Chairs: Ian Law (Copenhagen), Giuseppe Minniti (Rome)

- **A global perspective on PET imaging in neuro-oncology.**
  Andrew Scott (Melbourne) – *20'*
- **PET for surgery planning is just a toy!**
  Gelareh Zadeh (Rochester) – *8'*
- **PET for surgery planning is an indispensable tool!**
  Jörg-Christian Tonn (Munich) – *8'*

Audience voting: toy or tool?

- **PET for radiotherapy planning is just a toy!**
  Stephanie Combs (Munich) – *8'*
- **PET for radiotherapy planning is an indispensable tool!**
  Maximilian Niyazi (Tübingen) – *8'*

Audience voting: toy or tool?

- **PET for follow-up is just a toy!**
  Martin van den Bent (Rotterdam) – *8'*
- **PET for follow-up is an indispensable tool!**
  Anna Berghoff (Vienna) – *8'*

Audience voting: toy or tool?

16:45 – 17:00 Conclusions and Farewell Drinks

Nathalie L. Albert (Munich), Matthias Preusser (Vienna)

All contents are as per date of printing (27. April 2026).

The up-to-date scientific program is available in the online program on the symposium website.

The organizer reserves the right to modify the program in case of external or unforeseen circumstances and cannot assume any liability. No refunds can be granted in case of cancellations of speakers, lack of space in the lecture room or any other incidents during the symposium which are beyond the control of the organizer.

NOVARTIS

Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

FA-11625518 | 3/26

Rich Oncology Pipeline

Targeting multiple tumor types

Posters will be on display on both days in the Exhibition and Catering Are on the main floor.

A dedicated **poster viewing session** is scheduled on **Thursday, May 07, 2026 from 15.30 -16.30.** To enable discussion and interaction poster presenters or one of their group members are asked to be present at the poster board during this time.

A list of posters presented can be found from page 10 onwards.
Poster numbers will be shown on the poster boards.

Poster mounting and removal

Registration and poster mounting will be open from 08.45 on Thursday morning, May 07, 2026. **All posters must be removed after the symposium on Friday, May 08, 2026, until 18.00h.** Posters that have not been removed will be taken down and will not be stored or sent to the authors afterwards.

Only adhesive tape can be used to mount posters. Material will be available onsite.

Poster Topics

1. Brain Metastasis
2. Glioma
3. Meningioma
4. Other

Abstracts

Abstracts presented at the **NMN Symposium 2026** are available on the symposium website.

Poster List

Poster Nr.	Titel	First Name	Last Name	*Country*
1.01	Assessment of 18F-FET PET-based response to contemporary CNS-active systemic agents in patients with brain metastases using the PET RANO BM 1.0 criteria	Jana-Marie	Peplinski	*Germany*
1.02	Radiographic regression of parenchymal brain metastases after PRRT in metastatic well-differentiated neuroendocrine tumor: a case study	Joshua	Qian	*United States*
2.01	SSTR PET Characteristics of Newly Diagnosed Meningiomas: Correlation with Neuropathological Diagnosis and Molecular Profile	Thomas	Schabhüttl	*Germany*
2.02	Impact of postoperative somatostatin-receptor-targeted PET imaging on residual tumor detection and surgical assessment of re-resection in meningioma	Nina C.	Teske	*Germany*
2.03	Multi-pinhole SPECT/CT for meningioma imaging: a novel diagnostic approach	Kristóf	Apró	*Hungary*
2.04	Multimodal Imaging: MRI and 68Ga-DOTA-TATE PET/CT for Detection of Residual Meningioma with Transverse Sinus Invasion	Elif Reyhan	Aslan	*Türkiye*
2.05	SSTR SPECT/CT volumetric changes during ^{177}Lu-DOTATATE therapy and their relation to progression and quality of life in recurrent meningioma.	Stela	Asadurova	*Spain*
3.01	Translational Potential of MAO-B PET Imaging as a Biomarker in Glioblastoma	Justus	Thevis	*Germany*
3.03	Comparison of [^{18}F] Fluciclovine PET, [^{18}F] FDG PET, and Contrast-Enhanced MRI in the Preoperative Identification of High-Grade Glioma	Hiroto	Koga	*Japan*
3.04	The added value of serial FET PET imaging to diagnose tumor progression in patients with glioblastoma	Norbert	Galldiks	*Germany*
3.05	A Phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of fractionated intracavitary radioimmunotherapy with Lutetium-177 labeled 6A10 Fab fragments in patients with glioblastoma – an updated interim report	Wolfgang	Roll	*Germany*

3.06	**68Ga/177Lu-PSMA theranostics in recurrent high-grade glioma**	Anna Maria	Karlberg	*Norway*
3.07	**Functional connectivity decline in glioma patients is associated with metabolic tumor progression according to the PET RANO 1.0 criteria**	Manuel	Kraft	*Germany*
3.08	**The NMN-BBB score as a prognostic marker in newly diagnosed glioblastoma: a single-center, retrospective study**	Roman	Stürzl	*Germany*
3.09	**Noninvasive discrimination of CDKN2A/B status and WHO grading using [18F]FET-PET imaging in IDH-mutant astrocytoma**	Katharina J.	Müller	*Germany*
3.10	**The prognostic significance of TSPO-PET imaging in IDH-mutant glioma: a single-center, retrospective study**	Katharina J.	Müller	*Germany*
3.11	**[18F]FET PET characteristics in recurrent oligodendroglioma – considerations for clinical trials**	Maximilian	Mair	*Austria*
3.12	**Follow-up on the preclinical evaluation of [18F] AG-120, a radiotracer for the detection of the mutant isocitrate dehydrogenase 1 in a rat model of glioma**	Magali	Toussaint	*Germany*
3.13	**A Semi-Automated Approach to Glioblastoma Delineation on [18F]FET PET to Improve Automated Segmentation**	Anass	Hamdi	*Belgium*
3.14	**Significant uptake of a copper-64 labelled non-specific isotype antibody by myeloid cells in the tumor microenvironment of murine glioblastoma**	Lena	Wesser	*Germany*
3.15	**Prognostic significance of PET RANO 1.0 response in patients with newly diagnosed IDH wild-type glioblastoma and longitudinal FET PETs**	Isabelle	von Polenz	*Germany*
3.16	**Background Activity Assessment in 18F-FET PET Imaging**	Poh Hui	Phang	*Singapore*
3.18	**IPAX BrIGHT: Pivotal study of iodofalan (^{131}I) with or without lomustine vs lomustine alone for the treatment of patients with radiographically confirmed recurrent glioblastoma at first recurrence**	Nelleke	Tolbloom	*United States*
3.19	**IPAX-2: Phase 1 safety and dose finding study of iodofalan (^{131}I) plus standard of care in patients with newly diagnosed glioblastoma**	Nelleke	Tolbloom	*United States*

3.20	**Impact of Reconstruction Methods on Quantitative [18F]FET PET/CT Parameters in Pediatric Brain Tumor Imaging**	Tamara	Antonevskaya	*Russian Federation*
3.21	**Diagnostic accuracy of long-axial-field-of-view [18F]FET PET/CT in high-grade glioma – semi-quantitative cutoff values for tumour detection**	Michelle	Amon	*Switzerland*
3.22	**Multiparametric imaging [18F]FET PET characteristics improves differentiation of WHO grade 2 and higher-grade IDH-mutant glioma**	Enio	Barci	*Germany*
3.23	**Early-dominant TSR kinetics on dynamic F-DOPA PET: a radiotherapy-relevant biomarker for glioma recurrence**	Gabor	Sipka	*Hungary*
3.24	**Hijacking low-density lipoprotein receptors (LDLR) to target glioblastoma**	Izabela	Tworowska	*United States*
3.25	**Features of PET/CT with FET interpretation after proton radiarion therapy of patients with IDH wildtype glioblastoma**	Daniil	Susin	*Russian Federation*
3.26	**Subventricular zone involvement and metabolic phenotype: a combined MRI and ^{18}F-FET PET/CT biomarker for glioma prognosis**	Nina	Vikhrova	*Russian Federation*
3.27	**TSPO PET reveals dynamic myeloid activation in the skull bone marrow of glioblastoma patients**	Zeynep Ilgin	Kolabas	*Germany*
4.01	**Validation of an optimized 18F-FET PET/CT quantification protocol: single-slice background SUV and tumor SUVpeak enhance reproducibility and prognostic accuracy in glioma management**	Nina	Vikhrova	*Russian Federation*
4.02	**Impact of FET PET on Proton Radiotherapy Target Delineation**	Daniil	Susin	*Russian Federation*
4.03	**Benefit of [177Lu]Lu-HA-DOTATATE in bone metastases in relapsed medulloblastoma, a case report**	Sabine L.A.	Plasschaert	*Netherlands*

RadioMedix
INNOVATING THERANOSTICS

Advancing Radiopharmaceuticals

Innovative Radiopharmaceutical Development for Treatment of Brain Tumors

We advance innovative radiopharmaceutical drug development and contract manufacturing, guided by a steadfast commitment to patient-centered diagnostics and therapeutics and underpinned by scientific excellence.

OUR EXPERTISE

- Advancing our own clinical-stage pipeline for hard to treat cancer for 20 years
- Trusted, high-quality CDMO partner
- End-to-end drug discovery to commercialization
- FDA approved cGMP manufacturing, regulatory-ready
- Alpha & beta isotope expertise

RadioMedix

CONTACT US

info@radiomedix.com

www.radiomedix.com

An independent group committed to therapeutic progress to serve patient needs[1]

At Servier, we draw strength from our independence. Governed by a non-profit Foundation, our Group aspires to have a meaningful social impact, both for patients and for a sustainable world.[1]

As a leading global player in **cardiometabolism and venous diseases**, we aim to become a leading innovator in **oncology** and **neurology**. We intend to deliver targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and we invest nearly 20% of our brand-name revenue in R&D.[1]

In all these areas, **we include the patient voice** at each stage of the life cycle of a medicine.[1]

[1]**servier.com**

SERVIER
moved by you

M-GMPA-ALL-00714

We thank our valued partners for their support.

PLATINUM SPONSORS

Daiichi-Sankyo

NOVARTIS

SERVIER

GOLD SPONSORS

Telix

SILVER SPONSORS

AMGEN

Bristol Myers Squibb®

CARTHERA
Advanced Brain Therapy

GSK

itm
PASSION FOR PRECISION

MEDSIR
MEDICA SCIENTIA INNOVATION RESEARCH

novocure®

PERSPECTIVE® THERAPEUTICS

RadioMedix
INNOVATING THERANOSTICS

SERVIER

SIEMENS Healthineers

BRONZE SPONSORS

ABX

CURIUM™
LIFE FORWARD

HERMES MEDICAL SOLUTIONS

MindView
PERSONALIZED BRAIN CARE

GENERAL SPONSORS

MINUTE MEDICAL

Registration Opening Hours

Thursday, May 07, 2026: 08:45 – 17:30 hrs
Friday, May 08, 2026: 08:30 – 17:30 hrs

Location and Accessibility

Apothekertrakt Schloss Schönbrunn
Meidlinger Tor, Grünbergstraße, 1130 Vienna, Austria

The Apothekertrakt (Meidlinger Tor, Grünbergstraße, 1130 Vienna) is located next to the Schloss Schönbrunn. There are good public transport connections and the Apothekertrakt is within easy reach from the following stations: Schönbrunn (metro U4) and Schloss Schönbrunn (Tram 10, 60, as well as bus 10A).

If arriving by car, there is parking at APCOA Parkplatz Schönbrunn Wien (more detailed information available at www.apcoa.at/kurzparken/standorte/wien/schoenbrunn-wien-apcoa).

We recommend using public transportation whenever possible.

Cloakroom/Luggage compartment

Cloakroom and luggage compartment will be available but unattended; no liability will be assumed. You can find both at the entrance.

Opening hours:
Thursday, May 07, 2026: 08:45 – 17:30 hrs
Friday, May 08, 2026: 08:30 – 17:30 hrs

Social Media

Stay connected!
Follow us on LinkedIn and subscribe to our newsletter for updates and news.

Join the conversation! Use the hashtag #NMN2026 for your posts.

Nuclear Medicine and Neurooncology (NMN)

@nmnsymposium.bsky.social

Free-Wifi

Name: SchoenbrunnGroup
PW: Habsburger!

Conference Policy

Badges
Permission to the symposium (scientific sessions, exhibition and poster area) is only permitted to registered participants. Therefore, wearing your badge throughout the entire symposium is mandatory!

Language
The official language is English (no simultaneous translation available).

Certificate of attendance
Confirmations of attendance will be issued via email to all participants after the symposium.

Catering
During the lunch breaks, a light lunch as well as coffee and tea will be offered free of charge to participants wearing name badges in the exhibition area.

During the afternoon coffee breaks, refreshments (coffee, tea and snacks) will be served free of charge to participants wearing name badges in the exhibition area.

Additionally, water will be provided for free and coffee will be provided during the day in the exhibition area.

Smoking policy
The NMN 2026 Symposium is officially a “no-smoking-congress”. Note that smoking is banned in public buildings and private businesses in Vienna (e.g. restaurants, shops, public transport, entertainment venues and workplaces).

Sustainability
The NMN is committed to environmental sustainability, a responsible use of resources and sustainable congress materials. The organizer therefore asks you to keep these aspects in mind, e.g. by using public transport to get to the venue and networking events.

NETWORKING EVENT

Please note that the number of participants for the networking event is limited and advance registration is mandatory for the event. Admission will only be granted with a valid ticket. Check ticket availability at the registration desk.

No sponsoring is used to fund any part of the NMN Symposium 2026 Networking Event.

Location:	Plachuttas Grünspan Ottakringer Str. 266, 1160 Vienna
Public transport:	Metro U3 Station "Ottakring" Tram 10, 44, 46 Station "Maroltingergasse" Bus 45A 46 B Station "Ottakringer Friedhof"
Date:	Thursday, May 07, 2026
Time:	19:00 – 23:00 hrs

Individual arrival.

The City of Vienna and the Mayor Dr. Michael Ludwig are hosting this evening.

City of Vienna

Scientific Chair:
Nathalie Albert, Munich

Scientific Co-Chair:
Matthias Preusser, Vienna



SAVE THE DATE

NMN Symposium

22.-23. April 2027
Vienna, Austria

www.nmn-society.org

Nuclear Medicine and Neurooncology (NMN)

NOTES


An established global key player in the **radioisotope & radiopharmaceutical** field.
Find out more about us and our products.
www.itm-radiopharma.com
Follow us:
itm
PASSION FOR PRECISION

PERSPECTIVE THERAPEUTICS

Treating Cancer from the Inside Out®

Advancing Innovation in Radiopharmaceutical Cancer Therapy



^{212}Pb-based targeted radiotherapies for α-particle radiation delivery to cancer cells

α-radiation inducing complex double-stranded DNA breaks in targeted cells

Currently Recruiting (For Investigational Use Only)

Trial	Phase / Indication	NCT#
[^{212}Pb] VMT-α-NET	Phase 1/2 Neuroendocrine Tumors	05636618
[^{212}Pb] VMT01	Phase 1/2 Melanoma	05655312
[^{212}Pb] PSV359	Phase 1/2 FAP-α+ Solid Tumors	06710756

Learn More at Perspectivetherapeutics.com

Caution: For Investigational Use Only. Not Approved for Clinical Use.
No Safety or Efficacy Data Presented. All Details from Public Sources.